DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financi...(id-in capital 7915624 ...),Health

Date:8/11/2009

id-in capital 7,915,624 7,514,900 Accumulated deficit (144,310,565) (141,850,925) Accumulated other comprehensive loss 313,567 384,281 TOTAL SHAREHOLDERS' EQUITY 15,602,025 17,712,199 ---------- ---------- TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $23,984,505 $28,210,454 =========== ===========

    DUSA Pharmaceuticals, Inc.
    Consolidated Statement of Operations

                             Three-months ended          Six-months ended
                               June 30,                      June 30,
                        --------------------------   ------------------------
                            2009          2008          2009        2008
                        (Unaudited)     (Unaudited) (Unaudited)   (Unaudited)
                        ---------------------------  ------------------------
    Product revenues    $6,965,541      $8,112,239 $14,103,810   $16,041,739
    Cost of product
    revenues and
    royalties            1,440,864       1,787,694   3,379,090     3,488,011
                         ---------       ---------   ---------     ---------
        Gross margin     5,524,677       6,324,545  10,724,720    12,553,728

    Operating costs:
    Research and
     development         1,076,709       1,375,302   2,261,804     3,561,511
    Marketing and sales  3,037,311       3,496,233   6,447,415     6,553,434
    General and
     administrative      2,340,947       2,325,137   4,482,397     4,692,961
    Settlements, net        75,000         (47,825)     75,000      (283,425)
                            ------         -------      ------      --------
    Total operating
    costs                6,529,967       7,148,847  13,266,616    14,524,481

'/>"/>
SOURCE  DUSA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 
Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals